Stocks Novartis AG

More

  • Pharmaceuticals are priced at a bargain, said Mike Burnick, Weiss Capital Management director of research.

  • graphic_word_ofthe_street.jpg

    The Dow made another triple digit move on Monday this time soaring more than 400 points higher.

  • graphic_final_trade.jpg

    Here's our Fast Money Final Trade. Our gang gives you tomorrow's best trades, right now!

  • Cramer makes the call on viewers' favorite stocks.

  • pfizer_hq.jpg

    Pretty much all of biopharma is caught in the downdraft of the markets today with the notable exception of Dendreon (data) and ImClone Systems (a deal).

  • graphic_final_trade.jpg

    Here's our Fast Money Final Trade. Our gang gives you tomorrow's best trades, right now!

  • graphic_word_ofthe_street.jpg

    Investors hammered the Dow on Thursday as fear grew that even a $700 billion bailout won’t be enough to counter tight credit markets and a bleak economy.

  • graphic_final_trade.jpg

    Here's our Fast Money Final Trade. Our gang gives you tomorrow's best trades, right now!

  • The Fast Money traders told you the bottom won’t be in, until there’s panic like never before. Wait...

  • graphic_word_ofthe_street.jpg

    The Dow closed lower on Wednesday as nervous investors found it difficult to muster enthusiasm ahead of the Senate’s vote on a revamped $700 billion rescue plan.

  • webxtra_thumb.jpg

    Evidently you can run... and you 'can' hide. Find out where the traders think you should seek shelter from the current storm.

  • graphic_fast_money.jpg

    Find out what strategies the Fast Money traders are using to navigate this murderous market!

  • Which stocks were unfairly punished during Monday’s monster sell-off?

  • Of all the places to put money to work in Europe, the pharmaceutical sector is the most promising, a technical analyst told CNBC Thursday.

  • graphic_final_trade.jpg

    Here's our Fast Money Final Trade. Our gang gives you tomorrow's best trades, right now!

  • The market cap of Dow component Johnson & Johnson is a whopping $200 billion. Abbott Labs is valued at less than half that. But think of ABT as kind of a mini-me JNJ because like Johnson & Johnson, ABT has cobbled together a similar three-siloed business of drugs, devices and consumer products.

  • webxtra_thumb.jpg

    In Wednesday’s Web Extra the traders talk Deere & Co. Find out if this 'ag' name could grow your portfolio. Also Guy Adami has a biotech trade for you.

  • graphic_fast_money.jpg

    Bristol Myers offered a cool $4.5 billion for ImClone Thursday. Is now the time to play biotech?

  • In the last month healthcare has emerged as the best performing sector in the S&P. Are drug makers a cure for your portfolio in this economic downturn?

  • pharma_new2.jpg

    Roche Holdings' $43.7 billion bid to buy the rest of Genentech highlights drugmakers' growing reliance on biotech products.